WO1996026705A1 - Reduction of hair growth - Google Patents

Reduction of hair growth Download PDF

Info

Publication number
WO1996026705A1
WO1996026705A1 PCT/US1996/002791 US9602791W WO9626705A1 WO 1996026705 A1 WO1996026705 A1 WO 1996026705A1 US 9602791 W US9602791 W US 9602791W WO 9626705 A1 WO9626705 A1 WO 9626705A1
Authority
WO
WIPO (PCT)
Prior art keywords
hair growth
catechin
compound
composition
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/002791
Other languages
French (fr)
Inventor
Gurpreet S. Ahluwalia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP52641696A priority Critical patent/JP3853363B2/en
Priority to EP96908589A priority patent/EP0814754B1/en
Priority to BR9607061A priority patent/BR9607061A/en
Priority to AU51781/96A priority patent/AU720440B2/en
Priority to DE69617652T priority patent/DE69617652T2/en
Priority to CA002213411A priority patent/CA2213411C/en
Priority to AT96908589T priority patent/ATE209890T1/en
Publication of WO1996026705A1 publication Critical patent/WO1996026705A1/en
Priority to MXPA/A/1997/006523A priority patent/MXPA97006523A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • A61Q7/02Preparations for inhibiting or slowing hair growth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to a method of reducing unwanted hair growth in mammals.
  • a main function of mammalian hair is to provide environmental protection. However, that function has largely been lost in humans, in whom hair is kept or removed from various parts of the body essentially for cosmetic reasons. For example, it is generally preferred to have hair on the scalp but not on the face.
  • Green tea is a common beverage consumed throughout the world, particularly in Asian countries.
  • the tea leaves contain such chemically active components as flavanols, flavonoids, and phenolic acids. These components may represent as much as 1/3 the dry weight of green tea leaves.
  • the catechins present in the leaves are from the chemical class polyphenols. Four major catechins have been isolated from the leaves: epicatechin, epicatechin gallate, epigallocatechin, and epigallocatechin gallate. It has now been found that unwanted mammalian
  • catechin compound is a compound that includes the following ring structure
  • R ⁇ and R 2 are H.
  • catechin compounds include afzelchin, gallocatechin, catechin oligomers (procyanidins) , and oxidative dimers of catechin (theaflavin, theaflavin monogallate, theaflavin digallate) .
  • catechin compound encompasses compounds in which one or more of the hydroxy groups in the above ring structure are replaced by ester groups (e.g., alkyl esters such as methyl and ethyl esteric) .
  • Epicatechin, epicatechin gallate, epigallocatechin, epigallocatechin gallate were isolated from green tea leaves according to the procedure described by R. Agarwal et al., Cancer
  • the residue was dissolved in water and freeze-dried. This resulted in an off-white to slightly yellow dried residue of green tea polyphenola (GTP) .
  • GTP green tea polyphenola
  • the total yield of the polyphenolic fraction was 10.3%.
  • the percent composition of individual polyphenol component in the mixture was determined on a reverse-phase HPLC system. The HPLC analysis revealed four major catechin components in the mixture: epigal- locatechin (4.6%), epigallocatechin gallate (69.6%), epicatechin (6.7%) and epicatechin gallate (19.1%) .
  • the individual catechin components were further purified on a preparative reverse phase HPLC system.
  • the freeze-dried GTP's fraction was dissolved in water, and loaded on to a 40 x 300mm C-18 reverse phase column.
  • the catechin compounds were eluted from the column using a gradient elution with water (adjusted to pH 4.4 with formic acid) and ethanol.
  • the column eluent was collected at 1 min intervals HPLC fractions containing purified epigallocatechin, epigallocatechin gallate, epicatechin, and epicatechin gallate (as verified using analytical reverse phase system) were pooled and freeze-dried.
  • the catechin compound preferably is incorporated in a topical composition which includes a non-toxic dermatologically acceptable vehicle or carrier which is adapted to be spread upon the skin.
  • suitable vehicles are acetone, alcohols, or a cream, lotion, or gel which can effectively deliver the active compound.
  • a penetration enhancer may be added to the vehicle to further enhance the effectiveness of the formulation.
  • concentration of the catechin compound in the composition may be varied over a wide range up to a saturated solution, preferably from 0.1% to 40% by weight or even more; the reduction of hair growth increases as the amount of the catechin compound applied increases per unit area of skin.
  • a catechin compound can be used in purified form or as a mixture; for example the mixture of catechin compounds isolated from green tea leaves as previously described can be used without further purification.
  • the maximum amount effectively applied is limited only by the rate at which the catechin compound penetrates the skin. Generally, the effective amounts range from 100 to 3000 micrograms or more per square centimeter of skin.
  • the composition should be topically applied to a selected area of the body from which it is desired to reduce hair growth.
  • the composition can be applied to the face, particularly to the beard area of the face, i.e., the cheek, neck, upper lip, and chin.
  • the composition can also be applied to the legs, arms, torso or armpits.
  • the composition is particularly suitable for reducing the growth of unwanted hair in women suffering from hirsutism or other conditions.
  • the composition should be applied once or twice a day, or even more frequently, for at least three months to achieve a perceived reduction in hair growth. Reduction in hair growth is demonstrated when the frequency of hair removal
  • Hale intact Golden Syrian hamsters are considered acceptable models for human beard hair growth in that they display oval shaped flank organs, one on each side, each about 8 mm. in major diameter, which grow thick black and coarse hair similar to human beard hair. These organs produce hair in response to androgens in the hamster.
  • the flank organs of each of a group of hamsters are depilated by applying a thioglycolate based chemical depilatory (Surgex) .
  • a thioglycolate based chemical depilatory Surgex
  • the flank organs are shaved and the amount of recovered hair (hair mass) from each is weighed. Percent-reduction of hair growth is calculated by subtracting the hair mass (mg) value of the test compound treated side from the hair mass value of the vehicle treated side; the delta value obtained is then divided by the hair mass value of the vehicle treated side, and the resultant number is multiplied by 100.
  • the above-described assay will be referred to herein as the "Golden Syrian hamster" assay.
  • Preferred compositions provide a reduction in hair growth of at least about 35%, more preferably at least about 50%, and most preferably at least about 70% when tested in the Golden Syrian hamster assay.
  • Treatment Vehicle Dose pH Mixture A 1 5% 5.0 2.29 ⁇ .21 1.25 ⁇ .17 46 ⁇ 7 Mixture A 10% 4.5 2.21 ⁇ .17 0.58 ⁇ .ll 73 ⁇ 5 Mixture A 20% 5.0 2.84 ⁇ .21 0.42 ⁇ .10 85 ⁇ 4 Mixture A 30% 5.0 2.34 ⁇ .21 0.25 ⁇ .13 91 ⁇ 5 Control A NA 2 4.6 2.20 ⁇ .18 2.35 ⁇ .20 NI 3
  • Vehicle A Pure water (68%) , ethanol (16%) , propylene glycol (5%) , dipropylene glycol (5%) , benzyl alcohol (4%) and propylene carbonate (2%)
  • Epigallocatechin (EGC) , epigallocatechin gallate (EGCG) , epicatechin (EC) , and epicatechin gallate (ECG) purified as described previously, also were tested in a Golden Syrian hamster assay. The results are presented in Table 2. Among the four catechins, epigallocatechin gallate was found to be the most potent. The hair growth reductions ranged from 58 to 81%. In a dose response study, this compound was found to be quite effective even at a 1% concentration, which produced a 53% hair growth reduction.
  • Vehicle A Pure water (68%), ethanol (16%), propylene glycol (5%), dipropylene glycol (5%) , benzyl alcohol (4%) and propylene carbonate (2%)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mammalian hair growth is reduced by applying to the skin a dermatologically acceptable composition including a catechin compound.

Description

REDUCTION OF HAIR GROWTH The invention relates to a method of reducing unwanted hair growth in mammals.
A main function of mammalian hair is to provide environmental protection. However, that function has largely been lost in humans, in whom hair is kept or removed from various parts of the body essentially for cosmetic reasons. For example, it is generally preferred to have hair on the scalp but not on the face.
Various procedures have been employed to remove unwanted hair, including shaving, electrolysis, depilatory creams or lotions, waxing, plucking, and therapeutic antiandrogens. These conventional procedures generally have drawbacks associated with them. Shaving, for instance, can cause nicks and cuts and can also promote the perception of an increase in the rate of hair regrowth. Shaving also can leave stubble. Electrolysis, on the other hand, can keep a treated area free of hair for prolonged periods of time, but can be expensive, painful, and sometimes leaves scarring. Depilatory creams, though very effective, typically are not recommended for frequent use due to their high irritancy potential. Waxing and plucking can cause pain, discomfort, and poor removal of short hair. Finally, antiandrogens -- which have been used to treat female hirsutism -- can have unwanted side effects.
Green tea is a common beverage consumed throughout the world, particularly in Asian countries. The tea leaves contain such chemically active components as flavanols, flavonoids, and phenolic acids. These components may represent as much as 1/3 the dry weight of green tea leaves. The catechins present in the leaves are from the chemical class polyphenols. Four major catechins have been isolated from the leaves: epicatechin, epicatechin gallate, epigallocatechin, and epigallocatechin gallate. It has now been found that unwanted mammalian
(including human) hair growth -- particularly androgen- βtimulated hair growth -- can be reduced by applying to the skin a dermatologically acceptable composition including a catechin compound in an amount effective to reduce hair growth. The unwanted hair growth which is reduced may be normal hair growth, or hair growth that results from an abnormal or diseased condition. The preferred catechin compounds are the four major catechin compounds present in green tea leaves. λ "catechin compound", as used herein, is a compound that includes the following ring structure
OH
Figure imgf000004_0001
For (-) -epicatechin (EC), R^ and R2 are H. For
(-) -epicatechin gal late (ECG) , R^ is H and R2 is
Figure imgf000004_0002
For (-) -epigallocatechin (EGC) , R-^ is OH and R2 is H. And for (-) -epigallocatechin gallate (EGCG) , R^ is OH and R2 is the saune as in (-) -epicatechin gallate (ECG) . Other catechin compounds include afzelchin, gallocatechin, catechin oligomers (procyanidins) , and oxidative dimers of catechin (theaflavin, theaflavin monogallate, theaflavin digallate) . In addition, "catechin compound", as used herein, encompasses compounds in which one or more of the hydroxy groups in the above ring structure are replaced by ester groups (e.g., alkyl esters such as methyl and ethyl esteric) .
Epicatechin, epicatechin gallate, epigallocatechin, epigallocatechin gallate were isolated from green tea leaves according to the procedure described by R. Agarwal et al., Cancer
Research 52:3582-3588 (1992), with some modification. Dried green tea leaves were extracted with hot water at 80°C. under nitrogen. The hot water extraction was repeated twice. The residual leaves were further extracted with 80% ethanol by gently agitating at 25- 30°C. on a horizontal shaker at 125 rp for 1 hr. The water and the ethanol extracts were combined. The hydro-alcoholic (water-ethanol) extract was treated with chloroform to remove caffeine and pigments. The chloroform layer was separated from the hydro-alcoholic layer using a separatory funnel. The latter fraction was extracted three times under nitrogen with ethyl acetate. The ethyl acetate layer was separated and subjected to rotary evaporation to remove the organic solvent. The residue was dissolved in water and freeze-dried. This resulted in an off-white to slightly yellow dried residue of green tea polyphenola (GTP) . The total yield of the polyphenolic fraction was 10.3%. The percent composition of individual polyphenol component in the mixture was determined on a reverse-phase HPLC system. The HPLC analysis revealed four major catechin components in the mixture: epigal- locatechin (4.6%), epigallocatechin gallate (69.6%), epicatechin (6.7%) and epicatechin gallate (19.1%) .
The individual catechin components were further purified on a preparative reverse phase HPLC system. The freeze-dried GTP's fraction was dissolved in water, and loaded on to a 40 x 300mm C-18 reverse phase column. The catechin compounds were eluted from the column using a gradient elution with water (adjusted to pH 4.4 with formic acid) and ethanol. The column eluent was collected at 1 min intervals HPLC fractions containing purified epigallocatechin, epigallocatechin gallate, epicatechin, and epicatechin gallate (as verified using analytical reverse phase system) were pooled and freeze-dried. The catechin compound preferably is incorporated in a topical composition which includes a non-toxic dermatologically acceptable vehicle or carrier which is adapted to be spread upon the skin. Examples of suitable vehicles are acetone, alcohols, or a cream, lotion, or gel which can effectively deliver the active compound. One such vehicle is disclosed in co-pending application PCT/US93/0506A. In addition, a penetration enhancer may be added to the vehicle to further enhance the effectiveness of the formulation. The concentration of the catechin compound in the composition may be varied over a wide range up to a saturated solution, preferably from 0.1% to 40% by weight or even more; the reduction of hair growth increases as the amount of the catechin compound applied increases per unit area of skin. A catechin compound can be used in purified form or as a mixture; for example the mixture of catechin compounds isolated from green tea leaves as previously described can be used without further purification. The maximum amount effectively applied is limited only by the rate at which the catechin compound penetrates the skin. Generally, the effective amounts range from 100 to 3000 micrograms or more per square centimeter of skin.
The composition should be topically applied to a selected area of the body from which it is desired to reduce hair growth. For example, the composition can be applied to the face, particularly to the beard area of the face, i.e., the cheek, neck, upper lip, and chin. The composition can also be applied to the legs, arms, torso or armpits. The composition is particularly suitable for reducing the growth of unwanted hair in women suffering from hirsutism or other conditions. In humans, the composition should be applied once or twice a day, or even more frequently, for at least three months to achieve a perceived reduction in hair growth. Reduction in hair growth is demonstrated when the frequency of hair removal
(shaving, tweezing, depilatory use, waxing) is reduced, or the subject perceives less hair on the treated site, or quantitatively, when the weight of hair removed by shaving (i.e., hair mass) is reduced. Benefits of reduced hair removal frequency include convenience and less skin irritation.
Hale intact Golden Syrian hamsters are considered acceptable models for human beard hair growth in that they display oval shaped flank organs, one on each side, each about 8 mm. in major diameter, which grow thick black and coarse hair similar to human beard hair. These organs produce hair in response to androgens in the hamster. To evaluate the effectiveness of a particular catechin compound, or mixture of catechin compound, the flank organs of each of a group of hamsters are depilated by applying a thioglycolate based chemical depilatory (Surgex) . To one organ of each animal 10-25 μl . of vehicle alone once a day is applied, while to the other organ of each animal an equal amount of vehicle containing a catechin compound is applied.
After thirteen applications (one application per day for five days a week) , the flank organs are shaved and the amount of recovered hair (hair mass) from each is weighed. Percent-reduction of hair growth is calculated by subtracting the hair mass (mg) value of the test compound treated side from the hair mass value of the vehicle treated side; the delta value obtained is then divided by the hair mass value of the vehicle treated side, and the resultant number is multiplied by 100. The above-described assay will be referred to herein as the "Golden Syrian hamster" assay. Preferred compositions provide a reduction in hair growth of at least about 35%, more preferably at least about 50%, and most preferably at least about 70% when tested in the Golden Syrian hamster assay.
The mixture of catechins isolated from green tea leaves as described previously were tested in the Golden Syrian hamster assay. The mixture caused a dose dependent reduction of hair growth in the range of 46- 91%. The mixture was tested at a 5, 10, 20 and 30% dose. The results are presented in Table 1.
TABLE 1 Reduction of Hair Growth Using Mixture of Catechin Compounds
Treatment Vehicle Dose pH
Figure imgf000009_0001
Mixture A1 5% 5.0 2.29±.21 1.25±.17 46±7 Mixture A 10% 4.5 2.21±.17 0.58±.ll 73±5 Mixture A 20% 5.0 2.84±.21 0.42±.10 85±4 Mixture A 30% 5.0 2.34±.21 0.25±.13 91±5 Control A NA2 4.6 2.20±.18 2.35±.20 NI3
1 Vehicle A: Pure water (68%) , ethanol (16%) , propylene glycol (5%) , dipropylene glycol (5%) , benzyl alcohol (4%) and propylene carbonate (2%)
2 NA: Not applicable
3 NI: No inhibition
Epigallocatechin (EGC) , epigallocatechin gallate (EGCG) , epicatechin (EC) , and epicatechin gallate (ECG) , purified as described previously, also were tested in a Golden Syrian hamster assay. The results are presented in Table 2. Among the four catechins, epigallocatechin gallate was found to be the most potent. The hair growth reductions ranged from 58 to 81%. In a dose response study, this compound was found to be quite effective even at a 1% concentration, which produced a 53% hair growth reduction.
TABLE 2 Reduction of Hair Growth by Purified Catechin Compounds
Figure imgf000011_0001
Treatment Vehicle Dose EH Untreated Treated %Inhibition EGCG A1 1% 3.5 2.74±.30 1.26±.12 53±47 EGCG A 2.5% 3.5 2.32±.09 0.98±.14 58±6 EGCG A 5% 3.5 2.16±.30 0.45±.ll 67±15 EGCG A 10% 3.5 2.62±.24 0.45±.25 βl±ll ECG A 10% 4.5 2.94±.50 0.64±.14 73±7 EGC A 10% 3.5 2.15±.33 0.57±.17 65±12 EC A 10% 3.5 1.94±.25 0.74±.17 58±9 Control A NA2 4.0 2.39±.21 2.44±.38 NI3
Vehicle A: Pure water (68%), ethanol (16%), propylene glycol (5%), dipropylene glycol (5%) , benzyl alcohol (4%) and propylene carbonate (2%)
2 NA: Not applicable
3 NI: No inhibition
It will be appreciated by those skilled in the art that the invention can be performed within a wide range of equivalent parameters of composition and conditions without departing from the spirit or scope of the invention or of any embodiment thereof.

Claims

C A I M S
I. A method of reducing mammalian hair growth, comprising selecting an area of skin from which reduced hair growth is desired; and applying to said area of skin a dermatologically acceptable composition including a catechin compound in an amount effective to reduce hair growth. 2. The method of claim 1, wherein said catechin compound is epigallocatechin gallate.
3. The method of claim 1, wherein said catechin compound is epicatechin gallate.
4. The method of claim 1, wherein said catechin compound is epigallocatechin.
5. The method of claim 1, wherein said catechin compound is epicatechin.
6. The method of claim 1, wherein said composition includes a mixture of catechin compounds. 7. The method of claim 6, said method further comprising isolating said mixture of catechin compounds from green tea leaves.
8. The method of claim 1, wherein the concentration of said catechin compound in said composition is between 1% and 40%.
9. The method of claim 1, wherein the composition is applied to the skin in an amount of from 100 to 4000 micrograms of said catechin compound per square centimeter of skin. 10. The method of claim 1, wherein the composition is applied to the skin on the face of said mammal.
II. The method of claim 1, wherein the composition provides a reduction in hair growth of at least 30% when tested in the Golden Syrian hamster assay. 12. The method of claim 1, wherein the - 12 - composition provides a reduction in hair growth of at least 50% when tested in the Golden Syrian hamster assay.
13. The method of claim 1, wherein the composition provides a reduction in hair growth of at least 70% when tested in the Golden Syrian hamster assay.
14. The method of claim 1, wherein said mammal is a human. 15. The method of claim 1, wherein said area of skin comprises an area suffering from hirsutism. 16. The method of claim 1, wherein said composition further comprises a non-toxic, dermatologically acceptable carrier or vehicle. 17. The method of claim 1, wherein said catechin compound is selected from the group consisting of afzelchin, gallocatechin, catechin oligomers, and oxidative dimere of catechin.
18. A method of reducing mammalian hair growth, comprising selecting an area of skin from which reduced hair growth is desired; and applying to said area of skin a dermatologically acceptable composition comprising green tea leaves or a component extracted from green tea leaves in an amount effective to reduce hair growth.
19. The use of a catechin compound for the manufacture of a medicament for reducing mammalian hair growth.
20. The use according to claim 19, wherein said compound is as defined in any one of claims 2 to 18.
21. A method of producing a composition for reducing mammalian hair growth, which comprises selecting a catechin compound, and combining said compound, in an amount effective to reduce hair growth, with a non-toxic, dermatologically acceptable vehicle or carrier .
22. A method according to claim 21, wherein said vehicle or carrier is adapted to be spread upon the skin of a mammal. 23. A method according to claim 21, wherein said compound is as defined in any one of claims 2 to 18.
24. The new use of a catechin compound for reducing hair growth.
25. A composition when used for inhibiting mammalian hair growth, which includes a catechin compound in an amount effective to reduce hair growth and a non-toxic, dermatalogically acceptable vehicle or carrier.
26. A composition according to claim 25, wherein said compound is as defined in any one of claims 2 to 18.
PCT/US1996/002791 1995-02-28 1996-02-27 Reduction of hair growth Ceased WO1996026705A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP52641696A JP3853363B2 (en) 1995-02-28 1996-02-27 Reduce hair growth
EP96908589A EP0814754B1 (en) 1995-02-28 1996-02-27 Reduction of hair growth
BR9607061A BR9607061A (en) 1995-02-28 1996-02-27 Process for reducing hair growth in mammals using a catechin compound process for producing a composition for reducing hair growth in mammals and composition when used to inhibit hair growth in mammals
AU51781/96A AU720440B2 (en) 1995-02-28 1996-02-27 Reduction of hair growth
DE69617652T DE69617652T2 (en) 1995-02-28 1996-02-27 REDUCTION OF HAIR GROWTH
CA002213411A CA2213411C (en) 1995-02-28 1996-02-27 Reduction of hair growth
AT96908589T ATE209890T1 (en) 1995-02-28 1996-02-27 REDUCTION IN HAIR GROWTH
MXPA/A/1997/006523A MXPA97006523A (en) 1995-02-28 1997-08-27 Reduction of p growth

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/396,426 US5674477A (en) 1995-02-28 1995-02-28 Reduction of hair growth
US08/396,426 1995-02-28

Publications (1)

Publication Number Publication Date
WO1996026705A1 true WO1996026705A1 (en) 1996-09-06

Family

ID=23567148

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/002791 Ceased WO1996026705A1 (en) 1995-02-28 1996-02-27 Reduction of hair growth

Country Status (12)

Country Link
US (2) US5674477A (en)
EP (1) EP0814754B1 (en)
JP (1) JP3853363B2 (en)
AR (1) AR003410A1 (en)
AT (1) ATE209890T1 (en)
AU (1) AU720440B2 (en)
BR (1) BR9607061A (en)
CA (1) CA2213411C (en)
DE (1) DE69617652T2 (en)
ES (1) ES2164877T3 (en)
WO (1) WO1996026705A1 (en)
ZA (1) ZA961599B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481015B2 (en) 2003-03-04 2013-07-09 The Procter & Gamble Company Regulation of mammalian hair growth

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1275905B1 (en) * 1995-03-14 1997-10-24 Indena Spa POLYPHENOLIC FRACTIONS OF TEA, THEIR USE AND FORMULATIONS THAT CONTAIN THEM
US6146620A (en) * 1997-12-09 2000-11-14 Janowski; Leonard J. Shaving compositions useful in altering the growth of male beard hair
JP3973748B2 (en) 1998-01-14 2007-09-12 花王株式会社 Hair growth inhibitor
US6020006A (en) * 1998-10-27 2000-02-01 The Gillette Company Reduction of hair growth
US6121269A (en) * 1999-02-22 2000-09-19 Henry; James P. Reduction of hair growth
US6235737B1 (en) 2000-01-25 2001-05-22 Peter Styczynski Reduction of hair growth
US6299865B1 (en) 2000-05-02 2001-10-09 Peter Styczynski Reduction of hair growth
US7439271B2 (en) 2001-06-27 2008-10-21 The Gillette Company Reduction of hair growth
JP4759182B2 (en) * 2001-08-03 2011-08-31 花王株式会社 Water-soluble ginger extract
US7261878B2 (en) * 2001-08-10 2007-08-28 The Gillette Company Reduction of hair growth
US6743822B2 (en) 2001-08-10 2004-06-01 The Gillette Company Reduction of hair growth
US20030036561A1 (en) * 2001-08-10 2003-02-20 Peter Styczynski Reduction of hair growth
US7160921B2 (en) * 2002-01-29 2007-01-09 The Gillette Company Reduction of hair growth
US20040198821A1 (en) * 2002-01-29 2004-10-07 Hwang Cheng Shine Reduction of hair growth
US20030199584A1 (en) * 2002-04-11 2003-10-23 Ahluwalia Gurpreet S. Reduction of hair growth
US20040141935A1 (en) * 2003-01-21 2004-07-22 Peter Styczynski Reduction of hair growth
US7015349B2 (en) * 2003-03-26 2006-03-21 The Gillette Company Reduction of hair growth
US20050031699A1 (en) 2003-06-26 2005-02-10 L'oreal Porous particles loaded with cosmetically or pharmaceutically active compounds
US20050112075A1 (en) * 2003-11-25 2005-05-26 Hwang Cheng S. Reduction of hair growth
JP5070434B2 (en) * 2004-01-16 2012-11-14 ビーエーエスエフ、ビューティー、ケア、ソルーションズ、フランス、エスエーエス Uses of extracts of the genus Calyceae
US20050249685A1 (en) * 2004-04-27 2005-11-10 Natalia Botchkareva Reduction of hair growth
MX2007007624A (en) * 2004-12-22 2007-08-03 Gillette Co Reduction of hair growth with survivin inhibitors.
JP2008523158A (en) * 2004-12-22 2008-07-03 ザ ジレット コンパニー Reduction of hair growth
US20060263438A1 (en) * 2005-05-17 2006-11-23 L'oreal Gelled oil particles for targeting sebaceous glands and/or hair follicles
US7618956B2 (en) * 2005-05-31 2009-11-17 The Gillette Company Reduction of hair growth
US20070059264A1 (en) * 2005-09-13 2007-03-15 Ahluwalia Gurpreet S Reduction of hair growth
US20070203240A1 (en) * 2006-02-27 2007-08-30 The Procter & Gamble Company Personal care compositions and methods for regulating mammalian hair growth
US7727516B2 (en) * 2006-02-28 2010-06-01 The Procter & Gamble Company Reduction of hair growth
US8068624B2 (en) * 2008-04-28 2011-11-29 Beijing Funate Innovation Technology Co., Ltd. Thermoacoustic device
FR2944443B1 (en) 2009-04-21 2012-11-09 Arkema France METHOD FOR MANUFACTURING IMPREGNATED FREE POLYAMIDE FREE POWDER PARTICLES, AND POLYAMIDE FREE POWDER PARTICLES HAVING A CONTENT OF AT LEAST 25% BY WEIGHT OF AT LEAST ONE COSMETIC OR PHARMACEUTICAL AGENT
FR2953716B1 (en) 2009-12-16 2015-03-27 Oreal KIT FOR FORMULATING A COSMETIC PRODUCT
JP5903241B2 (en) * 2011-10-26 2016-04-13 花王株式会社 Hair growth inhibitor
ES2960500T3 (en) * 2019-07-17 2024-03-05 Cutaneon Skin & Hair Innnovations Gmbh Active agent for use in regulating hair growth

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2527927A1 (en) * 1982-06-07 1983-12-09 Kao Corp HAIR COSMETICS
JPS6253917A (en) * 1985-09-02 1987-03-09 Shiseido Co Ltd Hair cosmetic
JPH02202581A (en) * 1989-01-31 1990-08-10 Shiseido Co Ltd Inhibitor of photo-deterioration
WO1993024106A1 (en) * 1992-05-27 1993-12-09 L'oreal Composition comprising a proanthocyanidin oligomer encapsulated in a liposome
FR2708851A1 (en) * 1993-08-12 1995-02-17 Oreal Cosmetic composition comprising the combination of a nanopigment of metal oxides and an antioxidant, and its use for the protection of the skin and hair.

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426137A (en) * 1965-12-23 1969-02-04 Olin Mathieson Hair growth inhibiting by aminobenzophenones
US4161540A (en) * 1966-08-22 1979-07-17 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
GB1458349A (en) * 1972-12-05 1976-12-15 Sykora F Composition for and a process therewith of treating the hair and/or scalps of animals
US4039669A (en) * 1975-08-01 1977-08-02 Sterling Drug Inc. Composition for topical application and use thereof
US4139638A (en) * 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
FR2380775A1 (en) * 1977-02-22 1978-09-15 Sederma Sarl "AFTER-DEPILATION" COMPOSITION PROMOTING A PROGRESSIVE SLOWING OF HAIR REGROWTH
US4191775A (en) * 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
US4269831A (en) * 1979-05-09 1981-05-26 Sterling Drug Inc. Topical dermatological method of use of an androstenopyrazole
DE2943776A1 (en) * 1979-10-26 1981-05-14 Schering Ag Berlin Und Bergkamen, 1000 Berlin 17 (ALPHA) ALKYLSTEROIDS, THE PREPARATIONS CONTAINING THE SAME, AND METHOD FOR THE PRODUCTION THEREOF
US4439432A (en) * 1982-03-22 1984-03-27 Peat Raymond F Treatment of progesterone deficiency and related conditions with a stable composition of progesterone and tocopherols
JPS59187097A (en) * 1983-04-08 1984-10-24 花王株式会社 Shampoo composition
US4508714A (en) * 1983-11-14 1985-04-02 Tihomir Cecic Organic scalp lotion
US4885289A (en) * 1983-12-12 1989-12-05 Breuer Miklos M Alteration of character of male beard growth
US4720489A (en) * 1984-10-15 1988-01-19 Douglas Shander Hair growth modification with ornithine decarboxylase inhibitors
AU5626786A (en) * 1985-03-04 1986-09-24 Cellena (Cell Engineering) A.G. Melatonin compositions and uses thereof
US4935231A (en) * 1985-08-28 1990-06-19 Repligen Corporation Use of thioredoxin, thioredoxin-derived, or thioredoxin-like dithiol peptides in hair care preparations
JPS6284021A (en) * 1985-10-08 1987-04-17 Shiseido Co Ltd Testosterone-5alpha-reductase inhibitor
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
JPH085788B2 (en) * 1987-10-08 1996-01-24 花王株式会社 5α-reductase inhibitor
US5096911A (en) * 1990-06-25 1992-03-17 Ahluwalia Gurpreet S Alteration of rate and character of hair growth
WO1992003140A1 (en) * 1990-08-14 1992-03-05 Handelman Joseph H Enzymic alteration of hair growth
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
US5095007A (en) * 1990-10-24 1992-03-10 Ahluwalia Gurpreet S Alteration of rate and character of hair growth
US5181558A (en) * 1990-11-13 1993-01-26 Matsushita Refrigeration Company Heat exchanger
DE4038693A1 (en) * 1990-12-05 1992-06-11 Heverhagen Ulrich MEANS TO REDUCE GROWTH OR TO REMOVE HAIR ON HUMAN BODY
US5143925A (en) * 1990-12-20 1992-09-01 Douglas Shander Alteration of rate and character of hair growth
JPH04342535A (en) * 1991-07-12 1992-11-30 Rohto Pharmaceut Co Ltd Testosterone 5alpha-reductase inhibitor
GB9118979D0 (en) * 1991-09-04 1991-10-23 Unilever Plc Cosmetic composition
GB9118866D0 (en) * 1991-09-04 1991-10-23 Unilever Plc Cosmetic composition
JPH05109110A (en) * 1991-10-16 1993-04-30 Sony Corp Optical pickup device
JPH05301821A (en) * 1992-04-23 1993-11-16 Kao Corp Medicated cosmetic
JP3242997B2 (en) * 1992-06-25 2001-12-25 三井農林株式会社 Hyaluronidase activity inhibitor
US5364885A (en) * 1992-11-13 1994-11-15 Ahluwalia Gurpreet S Reduction of hair growth
US5411991A (en) * 1992-12-22 1995-05-02 Shander; Douglas Method of reducing hair growth employing sulfhydryl active compounds
FR2699818B1 (en) * 1992-12-24 1995-02-03 Oreal Cosmetic or pharmaceutical composition containing in combination a polyphenol and an extract of gingko.
US6239170B1 (en) * 1993-05-28 2001-05-29 Gurpreet S. Ahluwalia Inhibition of hair growth
FR2834216B1 (en) * 2001-12-27 2004-04-30 Pharmascience Lab COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE OXAZOLINE FOR INHIBITING LANGERHAN CELL MIGRATION, AND USES THEREOF

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2527927A1 (en) * 1982-06-07 1983-12-09 Kao Corp HAIR COSMETICS
JPS6253917A (en) * 1985-09-02 1987-03-09 Shiseido Co Ltd Hair cosmetic
JPH02202581A (en) * 1989-01-31 1990-08-10 Shiseido Co Ltd Inhibitor of photo-deterioration
WO1993024106A1 (en) * 1992-05-27 1993-12-09 L'oreal Composition comprising a proanthocyanidin oligomer encapsulated in a liposome
FR2708851A1 (en) * 1993-08-12 1995-02-17 Oreal Cosmetic composition comprising the combination of a nanopigment of metal oxides and an antioxidant, and its use for the protection of the skin and hair.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 107, no. 16, 19 October 1987, Columbus, Ohio, US; abstract no. 140869, T. SAKAMOTO: "Hair preparation containing tannins and bactericides" XP002009948 *
CHEMICAL ABSTRACTS, vol. 114, no. 16, 22 April 1991, Columbus, Ohio, US; abstract no. 149913, T. IKEDA: "Catechins for preventing deterioration of cosmetics, food and pharmaceuticals due to the sunlight." XP002009949 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481015B2 (en) 2003-03-04 2013-07-09 The Procter & Gamble Company Regulation of mammalian hair growth
US8591874B2 (en) 2003-03-04 2013-11-26 The Procter & Gamble Company Inhibition of mammalian hair growth

Also Published As

Publication number Publication date
MX9706523A (en) 1997-11-29
AU5178196A (en) 1996-09-18
DE69617652T2 (en) 2002-08-22
ES2164877T3 (en) 2002-03-01
US5776442A (en) 1998-07-07
AU720440B2 (en) 2000-06-01
US5674477A (en) 1997-10-07
JPH11501036A (en) 1999-01-26
DE69617652D1 (en) 2002-01-17
JP3853363B2 (en) 2006-12-06
CA2213411A1 (en) 1996-09-06
EP0814754B1 (en) 2001-12-05
BR9607061A (en) 1998-12-15
ZA961599B (en) 1996-09-05
CA2213411C (en) 2000-11-21
AR003410A1 (en) 1998-08-05
EP0814754A1 (en) 1998-01-07
ATE209890T1 (en) 2001-12-15

Similar Documents

Publication Publication Date Title
US5776442A (en) Reduction of hair growth
EP0700282B1 (en) Inhibition of hair growth
DE69509891T2 (en) INHIBITION OF HAIR GROWTH
JP3091782B2 (en) Slimming composition for cosmetics
JP2000501096A (en) Suppress hair growth
EP1124531A1 (en) Reduction of hair growth
EP0957891A1 (en) Reduction of hair growth
JP3223404B2 (en) Hair restorer
JP2003528123A (en) Cosmetic composition having a delay effect on the regeneration of unwanted hair
KR101322926B1 (en) A Composition for prevention of hair loss and promotion of hair growth comprising extracts of Eclipta prostrata, fractions thereof, terthienyl derivatives or pharmaceutically acceptable salts thereof
US20090082473A1 (en) Composition comprising resveratol and its topical use thereof for reducing human hair growth
KR20050074592A (en) Method of stimulating hair growth using benzopyrans
CA2449822C (en) Reduction of hair growth
EP2720673B1 (en) Compositions for reducing human hair growth
MXPA97006523A (en) Reduction of p growth
EP1726297B1 (en) Composition comprising wortmannin and its topical use for reducing human hair growth
JP4498593B2 (en) Hair restorer composition
JPH10316543A (en) Composition for head

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2213411

Country of ref document: CA

Ref country code: CA

Ref document number: 2213411

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/006523

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 526416

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996908589

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996908589

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1996908589

Country of ref document: EP